Petr Kaňovský

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia

R. Benecke, W. H. Jost, Petr Kaňovský et al. · Neurology · 2005 · 271 citations

Medicine, Neurology, Neuroscience +14

A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport<sup>®</sup>) in the Treatment of Spastic Equinovarus Deformity after Stroke

Sean J. Pittock, A. P. Moore, Orla Hardiman et al. · Cerebrovascular Diseases · 2003 · 201 citations

Medicine, Neurology, Rehabilitation Medicine +17

Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb Spasticity

Petr Kaňovský, Zoltán Dénes, Thomas Platz et al. · Clinical Neuropharmacology · 2009 · 119 citations

Medicine, Neurology, Rehabilitation Medicine +17

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

Massimo Filippi, Maria A. Rocca, Elisabetta Pagani et al. · Journal of Neurology Neurosurgery & Psychiatry · 2013 · 113 citations

Life Sciences, Neurology, Neuroscience +17